title: Newer patents in antimycobacterial therapy.
abstract: Tuberculosis caused by Mycobacterium tuberculosis is a global health emergency. This deadly disease has far-reaching social and economic implications. Diseased individuals need prolonged polypharmacy which is not without ill effects. Treatment compliance is often compromised contributing to rising resistance. HIV co-infection has further worsened the scenario. On the other hand, no new anti-TB drug has hit the market in last 4-5 decades. After a long latency, only the last few years have witnessed growing research in this direction and a widening anti-TB drug clinical pipeline. The compounds in preclinical stage of development have also shown a heartening increase. The present review is an attempt to discuss novel promising patents in this field.
authors.affiliation: Shahid Clinic, 8-Jayanti, 353/21, RB Mehta Road, Ghatkopar (East), Mumbai 400 077, India.
authors.forename: S K
authors.initials: SK
authors.lastname: Shahid
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use; D058492:Drug Repositioning; D005818:Genetic Engineering; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000502:physiology; D010330:Patents as Topic; D028321:Plant Preparations; D014376:Tuberculosis / Q000188:drug therapy; D032581:Tuberculosis Vaccines
chemical_list: D000995:Antitubercular Agents; D028321:Plant Preparations; D032581:Tuberculosis Vaccines